Search clinical trials for: fibroblast growth factor receptor (FGFR)

Total 57967 results

Steadman Philippon Research Institute
United States Department of Defense; Office of Naval Research (ONR)

Terminated

Losartan to Improve Hip Microfracture

Fibrosis | Hip Osteoarthritis | Cartilage Damage | Hip Impingement Syndrome

United States
Roswell Park Cancer Institute
AIM ImmunoTech Inc.

Terminated

Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer

Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Pharmacyclics LLC.

Completed

A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer

Lung Cancer

United States
Bayer

Completed

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein

Cancers With HER2 Expression

United States, United Kingdom
The Netherlands Cancer Institute
Boehringer Ingelheim; Merck Serono International SA

Completed

Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer (AFACET)

Carcinoma, Non-Small-Cell Lung

Netherlands
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

Endometrial Neoplasms

France, Canada, United States, Spain, United Kingdom, Italy, Taiwan, Korea, Republic of, Colombia, Australia, New Zealand, Brazil, Turkey, Poland, Israel, Argentina, Germany, Ireland, Japan, Mexico, Russian Federation
M.D. Anderson Cancer Center
Novartis

Completed

Trastuzumab and RAD001 in Patients With Human Epidermal Growth Receptor 2 (HER-2) Overexpressing Breast Cancer

Breast Cancer | Neoplasm Metastasis

United States
Sun Yat-sen University
First Affiliated Hospital, Sun Yat-Sen University; Sun Yat-Sen Memorial Hospital...

Active, not recruiting

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Breast Cancer | Neoadjuvant Chemotherapy

China
Oana Danciu, MD
Pfizer; Big Ten Cancer Research Consortium

Active, not recruiting

Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer

Metastatic Breast Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States
Kyushu University
Japan Agency for Medical Research and Development; Ministry of Health, Labour...

Active, not recruiting

Randomized Phase IIb Trial of DVC1-0101

Peripheral Arterial Disease | Intermittent Claudication

Japan
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy (CheckMate722)

Non-Small-Cell Lung Carcinoma

United States, China, Taiwan, Spain, Korea, Republic of, France, Canada, Hong Kong, Japan, Singapore
NorthShore University HealthSystem
Shire

Completed

The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 ( FGF23) in Chronic Kidney Disease

Metabolic Bone Disease

United States
MedSIR
Pfizer

Completed

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA)

Breast Cancer | Advanced Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Spain, Germany, France, United Kingdom, Italy, Slovenia
Beth Israel Deaconess Medical Center

Completed

FGF21 and Fructose Challenge in Humans

Fasting

United States
US Oncology Research
Millennium Pharmaceuticals, Inc.

Active, not recruiting

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Breast Cancer | Breast Tumors | Breast Carcinoma | Malignant Neoplasm of Breast

United States
Beth Israel Deaconess Medical Center

Completed

Regulation of FGF21 by Nutritional Challenges

Fasting | Non-alcoholic Fatty Liver Disease (NAFLD)

United States
NCIC Clinical Trials Group
Australasian Gastro-Intestinal Trials Group

Completed

Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

Quality of Life | Colorectal Cancer

Canada, Australia
Medical College of Wisconsin

Active, not recruiting

Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer

Breast Cancer | Invasive Breast Cancer

United States
Erasca, Inc.

Completed

A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC (HERKULES-2)

Advanced Non-squamous Non-small-cell Lung Cancer

United States
GlaxoSmithKline

Terminated

Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Participants With Hormone Receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Advanced or Metastatic Breast Cancer

Neoplasms

United States, Korea, Republic of, Canada, Spain, Australia, United Kingdom, France
Beijing Sanbo Brain Hospital

Completed

Glioblastoma Response Prediction to Apatinib

Glioblastoma

China
Fudan University

Completed

Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)

Non-small-cell Lung Cancer

China
Nuvation Bio Inc.

Withdrawn

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Breast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Cancer of Breast | Malignant Tumor of Breast | Breast Tumor | Cancer of the Breast

United States
MedImmune LLC

Completed

MEDI9447 Alone and in Combination With MEDI4736 in Adult Participants With Select Advanced Solid Tumors.

Solid Tumors

United States, Korea, Republic of, Australia
Eisai Inc.

Completed

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Locally Recurrent | Metastatic Breast Cancer ( HER2 Negative)

United States
Yonsei University

Withdrawn

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Recurrent/Advanced Gastric Cancer

Korea, Republic of
Pfizer

Completed

Treatment Patterns and Clinical Outcomes Among Patients Receiving Palbociclib Combinations for Hormone Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2 ) Advanced/Metastatic Breast Cancer in the Arabian Gulf Region

Breast Neoplasms

Qatar, United Arab Emirates, Saudi Arabia
University Hospitals Coventry and Warwickshire...

Active, not recruiting

Obstructive Sleep Apnoea and Cardiac Arrhythmias (OSCA)

Cardiovascular Diseases | Obstructive Sleep Apnea | Arrhythmia | Atrial Fibrillation New Onset

United Kingdom
University of California, Los Angeles
Loma Linda University

Completed

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

Secondary Hyperparathyroidism

United States
First Affiliated Hospital, Sun Yat-Sen University

Completed

Fibroblast Growth Factors 19 and 21 in Gestational Diabetes Mellitus

Gestational Diabetes Mellitus

China
University of Alabama at Birmingham
Eli Lilly and Company

Completed

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Stage IV Non-Small Cell Lung Cancer

United States
Hoffmann-La Roche

Completed

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel (PEONY)

Breast Cancer

China, Korea, Republic of, Taiwan, Thailand
AbbVie
Radiation Therapy Oncology Group

Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Glioblastoma | Gliosarcoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Germany, Hong Kong, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Portugal, Russian Federation, Singapor... and more
Hoffmann-La Roche

Completed

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Taipei Medical University WanFang Hospital

Completed

The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study

Paronychia | Epidermal Growth Factor Receptor Inhibitor

Taiwan
Benha University

Completed

Double J Stenting and Sildosin After URSL for Lower Ureteric Stones (DJ)

Lower Ureteric Stones | Ureteroscopic Lithotripsy | DJ Stenting

Egypt
Pfizer
Japan Breast Cancer Research Group (JBCRG)

Completed

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy (JBCRG-26)

Breast Cancer

Japan
University of Sydney
AstraZeneca; Australasian Lung Cancer Trials Group

Active, not recruiting

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease. (ILLUMINATE)

EGFR Mutant Advanced Non Small Cell Lung Cancer

Taiwan, Australia
University of Milano Bicocca

Active, not recruiting

Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7)

Advanced Breast Cancer

Italy
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Open Label Study of KRN23 on Osteomalacia in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Canada, Japan, France, Denmark
Synermore Biologics Co., Ltd.
Synermore Biologics USA Limited

Active, not recruiting

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

Solid Tumor | Epithelial Carcinoma

United States
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

United States, Korea, Republic of, Japan, Ireland, United Kingdom, France, Italy
Pfizer

Active, not recruiting

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Metastatic Breast Cancer

Korea, Republic of
Rush University Medical Center

Completed

Patterns of Prescribing and Monitoring of Palbociclib

Advanced Breast Cancer | Metastatic Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Hacettepe University

Completed

Serum Fibroblast Growth Factor-21 Levels During Prolonged Fasting

Fasting | Fibroblast Growth Factor-21

Turkey
First Affiliated Hospital of Zhejiang University
AstraZeneca

Active, not recruiting

First Line Osimertinib for EGFR Mutation-positive Non-Small Cell Lung Cancer in Real World Chinese Setting

Carcinoma, Non-Small-Cell Lung

China
iOMEDICO AG
Pfizer

Completed

Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant (INGE-B)

Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Germany
University of Pennsylvania

Suspended

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Hypertension | Diabetes Mellitus, Type 2 | Pre-diabetic | Elevated Blood Pressure

United States
AstraZeneca
Daiichi Sankyo, Inc.

Completed

Estimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low Status

Breast Cancer

United States, Germany, Italy, Korea, Republic of, United Kingdom, Portugal, Australia, Japan, Canada, France
Consorzio Oncotech

Completed

Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial) (GIM21)

Metastatic Breast Cancer

Italy

Search clinical trials for: fibroblast growth factor receptor (FGFR)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations